BACKGROUND In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically important. We examined how this change compared with measures of clinical meaningfulness. METHODS This is a secondary analysis of a 12 month open-label study of 100 patients (71 women) diagnosed with mild to moderate AD treated wi...

The introduction of Advanced Driver Assistance Systems (ADAS) in road traffic induces many complex questions. One of them is whether or not present legislation frameworks are able to accommodate a smooth development and market implementation of ADAS. This is strongly related to the aspect of traffic safety. The various aspects related to this issue are categorised based on an exploration of the...

We investigated whether adipose-derived adult stromal (ADAS) are of neural crest origin and the extent to which Notch 1 regulates their growth and differentiation. Mouse ADAS cells cultured in media formulated for neural stem cells (NSC) displayed limited capacity for self-renewal, clonogenicity, and neurosphere formation compared to NSC from the subventricular zone in the hippocampus. Although...

Objective: to investigate the extent that baseline cognitive impairment and intake adherence affected the 13-item alzheimer’s disease assessment scale – cognitive subscale (adas-cog) intervention response of a medical food in alzheimer’s disease (ad) patients. Design/setting/participants /intervention/measurements: this analysis was performed on data from a proof-of-concept study, consisting of...

BACKGROUND Infliximab pharmacokinetic studies have been performed in patients receiving chronic infliximab therapy. In these patients, infliximab antidrug antibodies (ADAs) increase infliximab clearance and decrease serum levels and drug efficacy. OBJECTIVE This study analyzed the pharmacokinetic effect of infliximab ADAs in healthy subjects receiving a single dose of intravenous infliximab. ...

BACKGROUND A minimum 4-point change at 6 months on the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) is deemed clinically important, but this cut-point has been little studied in relation to clinical meaningfulness. In an investigator-initiated, clinical trial of galantamine, we investigated the extent to which a 4-point change classifies goal attainment by individual patie...